Botulinum neurotoxin D uses synaptic vesicle protein SV2 and gangliosides as receptors. - Test2 - elhamkhani - TriplyDB

Botulinum neurotoxin D uses synaptic vesicle protein SV2 and gangliosides as receptors.

Botulinum neurotoxin D uses synaptic vesicle protein SV2 and gangliosides as receptors.

http://www.wikidata.org/entity/Q33869062

about

SNAP-23 and VAMP-3 contribute to the release of IL-6 and TNFα from a human synovial sarcoma cell line Emerging opportunities for serotypes of botulinum neurotoxins TNFα induces co-trafficking of TRPV1/TRPA1 in VAMP1-containing vesicles to the plasmalemma via Munc18-1/syntaxin1/SNAP-25 mediated fusion.Novel Ganglioside-mediated Entry of Botulinum Neurotoxin Serotype D into Neurons Structural insights into the functional role of the Hcn sub-domain of the receptor-binding domain of the botulinum neurotoxin mosaic serotype C/D Structure of dual receptor binding to botulinum neurotoxin B Crystal Structures of Botulinum Neurotoxin DC in Complex with Its Protein Receptors Synaptotagmin I and II Identification of the synaptic vesicle glycoprotein 2 receptor binding site in botulinum neurotoxin A Puzzling Out Synaptic Vesicle 2 Family Members Functions.Botulinum neurotoxin D-C uses synaptotagmin I and II as receptors, and human synaptotagmin II is not an effective receptor for type B, D-C and G toxins.Widespread sequence variations in VAMP1 across vertebrates suggest a potential selective pressure from botulinum neurotoxins.Preferential entry of botulinum neurotoxin A Hc domain through intestinal crypt cells and targeting to cholinergic neurons of the mouse intestine Cytotoxicity of botulinum neurotoxins reveals a direct role of syntaxin 1 and SNAP-25 in neuron survival.Tetanus toxin entry. Nidogens are therapeutic targets for the prevention of tetanus.Identification of fibroblast growth factor receptor 3 (FGFR3) as a protein receptor for botulinum neurotoxin serotype A (BoNT/A).Tetanus Toxin Hc Fragment Induces the Formation of Ceramide Platforms and Protects Neuronal Cells against Oxidative Stress.Diverse binding modes, same goal: The receptor recognition mechanism of botulinum neurotoxin.SRC family kinase inhibitors antagonize the toxicity of multiple serotypes of botulinum neurotoxin in human embryonic stem cell-derived motor neurons Activity of botulinum neurotoxin type D (strain 1873) in human neurons.Botulinum Neurotoxins Can Enter Cultured Neurons Independent of Synaptic Vesicle Recycling The receptor binding domain of botulinum neurotoxin serotype C binds phosphoinositides.Botulinum neurotoxins B and E translocate at different rates and exhibit divergent responses to GT1b and low pH Unique biological activity of botulinum D/C mosaic neurotoxin in murine species.A Novel Inhibitor Prevents the Peripheral Neuroparalysis of Botulinum Neurotoxins.Clinical uses of botulinum neurotoxins: current indications, limitations and future developments Progress in cell based assays for botulinum neurotoxin detection Botulinum Neurotoxin Serotype A Recognizes Its Protein Receptor SV2 by a Different Mechanism than Botulinum Neurotoxin B Synaptotagmin.N-linked glycosylation of SV2 is required for binding and uptake of botulinum neurotoxin A.Historical Perspectives and Guidelines for Botulinum Neurotoxin Subtype Nomenclature.Molecular dissection of botulinum neurotoxin reveals interdomain chaperone function.Current strategies for designing antidotes against botulinum neurotoxins.Infection, Pain, and Itch.Detection, differentiation, and identification of botulinum neurotoxin serotypes C, CD, D, and DC by highly specific immunoassays and mass spectrometry.Bacterial Signaling to the Nervous System through Toxins and Metabolites.Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology.Double anchorage to the membrane and intact inter-chain disulfide bond are required for the low pH induced entry of tetanus and botulinum neurotoxins into neurons.A camelid single-domain antibody neutralizes botulinum neurotoxin A by blocking host receptor binding.Engineered botulinum neurotoxin B with improved efficacy for targeting human receptors Integration of Synaptic Vesicle Cargo Retrieval with Endocytosis at Central Nerve Terminals.Identification and characterization of a novel botulinum neurotoxin.

P2860

Q24316444-8B410FF4-8E4B-498C-821C-F6CF424CC457 Q26859917-D481395B-5A3B-473E-A7B2-9B4F82436914 Q27348801-AFE4B81D-DF1F-4277-9B84-587DF8B3BD79 Q27668123-9F61FCFA-51A4-434B-9AB5-AC995AEAB395 Q27677003-AFE875FF-98EF-4B10-9B05-804333E4F2FE Q27678834-824C2A92-4972-43BB-A624-36ACB0A95AAB Q27679493-B287ED36-2141-45A5-9F3B-F9868F89EDE7 Q28581589-A3B503AA-ED80-404B-AD97-9495F4077F48 Q33710870-0CA8D1D3-8C4B-4743-A104-9E5D5D5ECE13 Q33793263-FF693562-58EB-451E-98A9-DFBF03E36BC1 Q33882815-DE33BA18-4319-4CF7-A1FE-32A84F2B5E58 Q34205889-41D8C5AD-8F75-48DD-AA14-91B4C2D26B00 Q34327453-5CE9DB31-2593-4019-AD07-40D92DCC62E2 Q34449930-44AD9D0C-FCAD-4E6B-A4D0-4CFCC089BD6B Q34733600-3C2C0D45-381B-4CA5-B695-AE94E0FEE78B Q34797732-1CF3D24C-FF64-42A1-9640-147956652640 Q35563112-EF19B885-9E32-47AC-BC9A-0E865989B568 Q35684016-C8DBF1F1-D9DF-427E-924F-FDD6D88C63BF Q35690475-FC69FADC-521E-4730-920B-0F349ACA80D5 Q35710270-8734A637-AB12-4E9A-91D3-98133C4D9DD1 Q35751422-D9C14EED-BA22-4BBE-857A-ED4B078422C6 Q36099792-59BE1809-F993-49A3-8986-9E80EC9E78E3 Q36211139-0131AEAF-4E12-47A6-86DB-3AAAE5F9FD17 Q36376074-A3C15696-83A8-471F-9FA7-716F890174AD Q36395728-D746BD0C-D77F-4F40-B849-0C0BE6369C84 Q36818335-AEDE0A82-14C7-46F6-803B-75FCDFD47D11 Q36946982-14A49500-D35D-4AA2-9220-EE603730A96F Q37276819-00F8FBF1-17CC-4A1F-8397-4FC87772DA69 Q37641175-5AF3288C-DDF4-44C4-B19A-4639E37B1F63 Q38080382-8950D5BA-558F-41A3-9A16-E230BFDE2B3F Q38187441-FE93619A-F112-4B8A-9514-761E40E38961 Q38763491-310774E6-20C3-485E-A55F-6648692EDE75 Q38847565-138DEC85-CE68-4C8F-B965-77980D768906 Q39075039-BAC28AD0-051A-4DFB-A52C-C65C56C21484 Q39207459-B51B1F87-9928-4001-8F16-0AC315141FC3 Q39500669-68A6182B-D9AD-42E3-932F-E8D3F641A36A Q40102969-BA791753-A0D2-4EF7-B0CE-AF8FFC0818BC Q40971832-90BF7B9D-BC91-446C-8ECA-46D241494ABC Q41222236-10013AEA-3BF3-4740-86F9-5CD8055EEAEF Q41245604-8D7C6648-2A6F-4886-83CE-0EF2C887A0AF

P2860

Botulinum neurotoxin D uses synaptic vesicle protein SV2 and gangliosides as receptors.

http://www.wikidata.org/entity/Q33869062

description

2011 nî lūn-bûn

@nan

2011 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մարտին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Botulinum neurotoxin D uses synaptic vesicle protein SV2 and gangliosides as receptors.

@ast

Botulinum neurotoxin D uses synaptic vesicle protein SV2 and gangliosides as receptors.

@en

type

label

Botulinum neurotoxin D uses synaptic vesicle protein SV2 and gangliosides as receptors.

@ast

Botulinum neurotoxin D uses synaptic vesicle protein SV2 and gangliosides as receptors.

@en

prefLabel

Botulinum neurotoxin D uses synaptic vesicle protein SV2 and gangliosides as receptors.

@ast

Botulinum neurotoxin D uses synaptic vesicle protein SV2 and gangliosides as receptors.

@en

P1433

Q33869062-55AC1E3D-A0AE-49CC-9227-7AE0B7C35EA0

P1476

Q33869062-63E7F3B7-2014-405B-9BAE-E917DD016118

P2093

Q33869062-396874B1-73BD-4662-A0E6-570355B622AE

Q33869062-69DE8DD9-61E8-420C-B88E-40246BDDAF83

Q33869062-86A4D48B-185F-445B-AD26-A13EA80EB118

Q33869062-8B054E2A-8063-43A4-9798-059A9A0060DB

P2860

Q33869062-020A75A4-E131-408A-93E6-167FE4A0A4E2

Q33869062-0606DB00-7B37-4A9A-B9DF-98FE3B659C32

Q33869062-076B4C71-4CFE-4508-881A-3E72C7C185B7

Q33869062-0BABBD77-8F43-446C-B6CC-280681241741

Q33869062-0D945B8B-B879-415C-8BF4-E006DDBC7245

Q33869062-0F192ED7-6CE2-45EF-9260-13F6AD6D2736

Q33869062-10320F1A-D3B4-41DB-AEA6-C83632744C30

Q33869062-14C9DE68-C364-4FEB-B457-20492968AD63

Q33869062-18A73677-BDF0-4FC8-ACC5-006A6D1E8878

Q33869062-1A5C5F2E-DFD9-4C99-8243-2B17C367D3D7

P304

Q33869062-8C03A344-25CF-45DE-9B8A-B8DEDE69588C

P31

Q33869062-DF10BBDF-3EB5-4185-B218-68B34BD6C9C3

P356

Q33869062-9FB0BFD2-E43A-45D3-9C58-913FE13F1D0F

P433

Q33869062-4CDDDB4D-6A52-4853-9567-DCD51E30F432

P478

Q33869062-F6BAFD88-85C4-4573-B223-145AC8485121

P577

Q33869062-B97A5ABC-C94D-42E5-A78C-51021A528F1E

P5875

Q33869062-F3636B39-E944-4030-A140-5185F4833AF0

P698

Q33869062-A642C152-2E43-4EE0-ADCD-27F64844827F

P932

Q33869062-F4453C05-E43D-4D4A-A488-1E65A7C4490F

P356

JOURNAL.PPAT.1002008

P1433

P1476

Botulinum neurotoxin D uses synaptic vesicle protein SV2 and gangliosides as receptors.

@en

P2093

Eric A Johnson

http://www.w3.org/2001/XMLSchema#string

Lisheng Peng

http://www.w3.org/2001/XMLSchema#string

Min Dong

http://www.w3.org/2001/XMLSchema#string

William H Tepp

http://www.w3.org/2001/XMLSchema#string

P2860

Botulinal neurotoxins: revival of an old killer

Botulinum Toxin as a Biological Weapon: Medical and Public Health Management

Properties and use of botulinum toxin and other microbial neurotoxins in medicine

The synaptic vesicle cycle

Brain contains two forms of synaptic vesicle protein 2

Membrane fusion: grappling with SNARE and SM proteins

Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B

Structural basis of cell surface receptor recognition by botulinum neurotoxin B

Botulinum neurotoxin B recognizes its protein receptor with high affinity and specificity

Crystal Structure of Botulinum Neurotoxin Type A in Complex with the Cell Surface Co-Receptor GT1b—Insight into the Toxin–Neuron Interaction

P304

e1002008

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PPAT.1002008

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2011-03-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51042254

http://www.w3.org/2001/XMLSchema#string

P698

21483489

http://www.w3.org/2001/XMLSchema#string

P932

3068998

http://www.w3.org/2001/XMLSchema#string